H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $5.45.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.45 and a one-year low of $0.62. Currently, PDS Biotechnology has an average volume of 535.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.